

Lexaria Bioscience Corp.

09:45 14 Jan 2020

Lexaria Bioscience strikes licensing pact to provide DehydraTECH to Cannadips CBD

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP), an innovator in drug delivery platforms, revealed Tuesday that it has sealed an agreement to provide its patented DehydraTECH technology to Cannadips CBD.

The Kelowna, British Columbia-based company is seeing increased demand for its DehydraTECH, which masks unwanted tastes, improves onset speed and increases the bioavailability of active pharmaceutical ingredients in a simple and cost-effective platform.

Essentially, DehydraTECH allows CBD and other oils to be dehydrated into an odourless, tasteless powder and mixed with xanthan gum, cornflour and other base ingredients which can then be added to foods, drinks and creams. It also allows drugs and vitamins - in the case of cannabis, CBD - to enter the bloodstream faster than existing drug delivery platforms.

READ: Lexaria Bioscience is seeing increased demand for its DehydraTECH drug delivery system

Meanwhile, Humboldt County, California-based Cannadips CBD channels one of the most effective methods of smokeless CBD dosing with its Original Smokeless CBD Cannabis Dip Pouch, and the Original Hemp CBD Dip Pouch. Each tin of Cannadips contains 15 pouches with 10 mg of hemp-derived CBD per pouch, no tobacco and no nicotine, and only natural sweeteners.

Lexaria has been working with the Boldt Runners team behind the scenes to elevate the product experience.

Fast-acting, high absorption technology

The company said DehydraTECH is "perfectly suited" to improve the dipping experience through its fast-acting, high absorption technology that improves the consumer experience.

"Since Cannadips uses terpene-rich multi-spectrum oils as base ingredients, DehydraTECH is able to reduce throat irritation normally associated with some terpenes," noted the company. Inferior products try to get around this problem by utilizing less efficacious CBD isolate without terpenes that lack the entourage effect derived from multi-spectrum oils.

"In our quest to create the ultimate smokeless, oral cannabinoid experience for our customers, we found that the DehydraTECH technology solves many challenges and propels the product forward as we pioneer this product category," said Case Mandel, who is the co-founder and CEO of the Boldt Runners Corporation.


"Through our strong distribution partnership with Kretek International, and our family of strategic retail partners including Sheetz, Kwiktrip, and Circle K we are stoked for the DehydraTECH technology to shine through our tins," he added.

Cannadips brand is widely distributed

Price: 0.63

Market Cap: \$50.85 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	1.95	0.4

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Cannadips is currently rolling out tins nationally via Circle K and is in nearly 5,000 stores in the US with additional distribution in Europe.

Lexaria Bioscience CEO Chris Bunka said Lexaria is "very happy" to be working with Cannadips to create "next-generation" dipping products.

"We feel that with our technology, and our team backing the Boldt Runners (Cannadips), we can continue to push the boundaries of the category in partnership even further," said Bunka.

Lexaria's licensing agreement grants Cannadips CBD exclusive rights for the US market for 10 years and a renewal option for an additional 5 years. It also offers an option to expand the licence to Europe, Mexico and/or Canada and contains minimum performance provisions to maintain exclusivity.

"This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination," said Lexaria board member Brian Quigley, who is also an advisor to the Boldt Runners Corporation.

"We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine," he added.

On January 29, the two companies will be presenting "The Cannadips Hoop House Experience" at the two-day 2020 Tobacco Plus Expo, in Booth Number 6162, in Las Vegas.

The event will be marked by DeeJay Theory spinning and the debut of Cannadips' new Wintergreen and Mango flavors. The firm will also launch the Humboldt Collection, a unique twist on traditional "straight" dip flavors utilizing terpenes.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).